C21 Investments Inc (CXXIF)
0.243
0.00 (0.00%)
USD |
OTCM |
Sep 20, 09:43
C21 Investments Enterprise Value: 28.72M for Sept. 19, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 19, 2024 | 28.72M |
| September 18, 2024 | 26.50M |
| September 17, 2024 | 28.30M |
| September 16, 2024 | 28.90M |
| September 13, 2024 | 28.85M |
| September 12, 2024 | 26.50M |
| September 11, 2024 | 30.10M |
| September 10, 2024 | 30.34M |
| September 09, 2024 | 30.34M |
| September 06, 2024 | 27.10M |
| September 05, 2024 | 29.80M |
| September 04, 2024 | 29.98M |
| September 03, 2024 | 28.90M |
| August 30, 2024 | 27.56M |
| August 29, 2024 | 27.10M |
| August 28, 2024 | 27.70M |
| August 27, 2024 | 25.91M |
| August 26, 2024 | 28.12M |
| August 23, 2024 | 29.72M |
| August 22, 2024 | 27.70M |
| August 21, 2024 | 28.42M |
| August 20, 2024 | 29.02M |
| August 19, 2024 | 32.98M |
| August 16, 2024 | 31.30M |
| August 15, 2024 | 28.18M |
| Date | Value |
|---|---|
| August 14, 2024 | 32.50M |
| August 13, 2024 | 28.02M |
| August 12, 2024 | 27.10M |
| August 09, 2024 | 29.08M |
| August 08, 2024 | 31.15M |
| August 07, 2024 | 30.10M |
| August 06, 2024 | 32.80M |
| August 05, 2024 | 30.10M |
| August 02, 2024 | 29.62M |
| August 01, 2024 | 33.40M |
| July 31, 2024 | 33.82M |
| July 30, 2024 | 37.90M |
| July 29, 2024 | 33.58M |
| July 26, 2024 | 31.53M |
| July 25, 2024 | 30.10M |
| July 24, 2024 | 30.10M |
| July 23, 2024 | 33.29M |
| July 22, 2024 | 31.30M |
| July 19, 2024 | 28.94M |
| July 18, 2024 | 32.50M |
| July 17, 2024 | 32.50M |
| July 16, 2024 | 32.32M |
| July 15, 2024 | 30.10M |
| July 12, 2024 | 29.92M |
| July 11, 2024 | 30.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
24.46M
Minimum
Dec 20 2023
240.76M
Maximum
Feb 11 2021
65.67M
Average
55.59M
Median
Enterprise Value Benchmarks
| Acasti Pharma Inc | 9.794M |
| Aurinia Pharmaceuticals Inc | 699.06M |
| Edesa Biotech Inc | 12.09M |
| Lexaria Bioscience Corp | 40.92M |
| Xenon Pharmaceuticals Inc | 2.379B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.412M |
| Revenue (Quarterly) | 6.596M |
| Total Expenses (Quarterly) | 7.436M |
| EPS Diluted (Quarterly) | -0.01 |
| Gross Profit Margin (Quarterly) | 30.79% |
| Profit Margin (Quarterly) | -21.41% |
| Earnings Yield | -15.06% |
| Operating Earnings Yield | 0.26% |
| Normalized Earnings Yield | -12.33 |